Home
About
Overview
Sharing Data
ORCID
Help
History (14)
A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.
A double-blind study of the discontinuation of ragweed immunotherapy.
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Multifocal fibrosclerosis: a new case report and review of the literature.
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.
See All 14 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother. 2005 Jan; 6(1):131-9.
View in:
PubMed
subject areas
Azetidines
Cholesterol, HDL
Disease Management
Drug Therapy, Combination
Dyslipidemias
Ezetimibe
Humans
Lipoproteins, LDL
Simvastatin
authors with profiles
Michael H. Davidson